Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative

M. Baba, H. Tanaka, E. De Clercq, R. Pauwels, J. Balzarini, D. Schols, H. Nakashima, C. F. Perno, R. T. Walker, T. Miyasaka

Research output: Contribution to journalArticlepeer-review

Abstract

A novel 6-substituted acyclouridine derivative, 1-[(2-hydroxy-ethoxy) methyl]-6-phenylthiothymine (HEPT), has proved to be a potent and selective inhibitor of human immunodeficiency virus type 1 (HIV-1) in vitro. HEPT inhibits HIV-1 replication in various T4 cell cultures as well as peripheral blood lymphocytes and macrophages. The 50% antiviral effective concentration for HIV-1 (HTLV-IIIB) in MT-4 cells is 7.0 μM, while the 50% cytotoxic concentration for mock-infected MT-4 cells is 740 μM. Although HEPT is inhibitory to various strains of HIV-1, it has no effect on the replication of other retroviruses including HIV type 2. In contrast with the dideoxynucleoside (i.e. azidothymidine) 5′-triphosphates, the triphosphate of HEPT does not interact with HIV-1 reverse transcriptase. The mechanism of action of HEPT remains subject of further study.

Original languageEnglish
Pages (from-to)1375-1381
Number of pages7
JournalBiochemical and Biophysical Research Communications
Volume165
Issue number3
DOIs
Publication statusPublished - Dec 30 1989

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Molecular Biology

Fingerprint

Dive into the research topics of 'Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative'. Together they form a unique fingerprint.

Cite this